LogicBio Therapeutics (OTCMKTS:LOGC) Hits New 1-Year High – Here’s What Happened

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC)’s stock price hit a new 52-week high on Monday . The stock traded as high as $15.25 and last traded at $15.1850, with a volume of 29037 shares trading hands. The stock had previously closed at $14.87.

LogicBio Therapeutics Stock Up 0.7%

The company has a quick ratio of 1.24, a current ratio of 1.87 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $685.05 million, a PE ratio of -20.52 and a beta of 2.11. The firm’s fifty day moving average is $11.35 and its 200-day moving average is $9.60.

LogicBio Therapeutics (OTCMKTS:LOGC) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10). The business had revenue of $33.60 million during the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.